I

Incyte Corp
D

INCY

72.420
USD
-1.05
(-1.43%)
مغلق
حجم التداول
41,753
الربح لكل سهم
6
العائد الربحي
-
P/E
805
حجم السوق
13,951,731,033
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ABBV
    ABBV
    -3.460
    (-2.00%)
    169.130 USD
    AMGN
    AMGN
    -1.26
    (-0.46%)
    273.59 USD
    BMY
    BMY
    0.025
    (0.04%)
    57.075 USD
    GILD
    GILD
    0.070
    (0.08%)
    93.020 USD
    MRK
    MRK
    -0.560
    (-0.58%)
    95.670 USD
    REGN
    REGN
    -7.47
    (-1.09%)
    679.85 USD
    VRTX
    VRTX
    0.08
    (0.02%)
    428.09 USD
    المزيد
الأخبار
المقالات

العنوان: Incyte Corp

القطاع: Healthcare
الصناعة: Biotechnology
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.